Table 1 |
|||||
|
Treatments received by the patients and SLEDAI score at the time of analysis |
|||||
|
Patient characteristics |
|||||
|
Patient |
Sex |
Daily prednisone dose* |
Other treatment |
SLEDAI** |
%CD27+IgD+ |
|
|
|||||
|
1 |
F |
LOW |
HCQ |
4 |
7 |
|
2 |
F |
MEDIUM |
CYC |
16 |
9 |
|
3 |
F |
HIGH |
- |
8 |
1 |
|
4 |
F |
LOW |
- |
4 |
3 |
|
5 |
F |
- |
HCQ |
2 |
7 |
|
6 |
F |
LOW |
- |
15 |
3 |
|
7 |
F |
- |
HCQ |
0 |
4 |
|
8 |
F |
HIGH |
AZA |
10 |
5 |
|
9 |
F |
- |
- |
0 |
8 |
|
10 |
F |
- |
HCQ |
0 |
11 |
|
11 |
F |
- |
HCQ |
0 |
17 |
|
12 |
F |
LOW |
MMF |
10 |
4 |
|
13 |
F |
HIGH |
AZA |
1 |
3 |
|
14 |
F |
- |
HCQ |
2 |
3 |
|
15 |
F |
MEDIUM |
HCQ |
8 |
8 |
|
16 |
F |
HIGH |
HCQ |
0 |
13 |
|
17 |
F |
- |
- |
0 |
8 |
|
18 |
M |
LOW |
HCQ |
4 |
12 |
|
19 |
F |
LOW |
HCQ |
2 |
6 |
|
20 |
F |
LOW |
- |
0 |
2 |
|
21 |
F |
MEDIUM |
HCQ |
5 |
7 |
|
22 |
F |
HIGH |
HCQ |
19 |
9 |
|
23 |
F |
LOW |
- |
8 |
2 |
|
24 |
F |
LOW |
- |
4 |
21 |
|
25 |
F |
- |
- |
0 |
7 |
|
26 |
F |
LOW |
AZA |
1 |
7 |
|
27 |
M |
LOW |
AZA |
0 |
13 |
|
28 |
F |
- |
HCQ |
0 |
18 |
|
29 |
F |
- |
- |
11 |
6 |
|
30 |
F |
- |
HCQ |
13 |
3 |
|
31 |
F |
LOW |
AZA |
0 |
4 |
|
32 |
M |
- |
- |
0 |
6 |
|
33 |
F |
- |
HCQ |
4 |
8 |
|
34 |
F |
LOW |
HCQ |
8 |
4 |
|
35 |
M |
HIGH |
- |
8 |
6 |
|
36 |
F |
- |
HCQ |
0 |
11 |
|
37 |
F |
- |
HCQ |
0 |
25 |
|
38 |
F |
- |
- |
3 |
8 |
|
39 |
F |
- |
HCQ |
1 |
27 |
|
40 |
F |
- |
AZA/RX |
0 |
2 |
|
41 |
F |
- |
- |
0 |
24 |
|
42 |
F |
- |
HCQ |
0 |
4 |
|
43 |
F |
- |
- |
0 |
6 |
|
44 |
F |
- |
MTX |
0 |
8 |
|
45 |
F |
- |
- |
0 |
13 |
|
46 |
F |
- |
- |
0 |
28 |
|
47 |
F |
- |
HCQ |
0 |
2 |
|
48 |
F |
LOW |
HCQ |
0 |
16 |
|
49 |
F |
- |
HCQ |
1 |
5 |
|
50 |
F |
- |
- |
0 |
3 |
|
51 |
F |
- |
HCQ/MTX |
0 |
8 |
|
52 |
F |
- |
HCQ |
0 |
17 |
|
53 |
F |
- |
- |
0 |
33 |
|
54 |
F |
- |
HCQ |
0 |
6 |
|
55 |
F |
LOW |
MMF |
4 |
15 |
|
56 |
F |
- |
HCQ |
0 |
8 |
|
57 |
M |
- |
LFN |
4 |
31 |
|
58 |
F |
- |
LFN |
0 |
10 |
|
59 |
F |
LOW |
MTX |
4 |
5 |
|
60 |
F |
LOW |
MTX |
0 |
5 |
|
61 |
F |
- |
- |
0 |
4 |
|
62 |
F |
- |
HCQ |
1 |
7 |
|
63 |
F |
LOW |
MMF |
0 |
15 |
|
64 |
F |
- |
- |
0 |
3 |
|
65 |
F |
MEDIUM |
HCQ/MTX |
2 |
2 |
|
66 |
M |
LOW |
- |
0 |
13 |
|
67 |
F |
LOW |
- |
0 |
13 |
|
68 |
F |
- |
- |
0 |
17 |
|
69 |
F |
- |
AZA |
1 |
4 |
|
|
|||||
|
*LOW (≤10 mg/day); MEDIUM (≤30 mg/day); HIGH (>30 mg/day). AZA: azathioprine; HQC: hydroxychloroquine; CYC: cyclophosphamide; LFN: leflunomide MMF: mycophenolate mofetil; MTX: methotrexate; RX: rituximab; **SLEDAI: Systemic Lupus Erythematosus Disease Activity Index. |
|||||
|
Rodríguez-Bayona et al. Arthritis Research & Therapy 2010 12:R108 doi:10.1186/ar3042 |
|||||
